Search filters

Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 170
  • 696
  • 449
  • 14
  • 31
  • 1
  • 4
  • 648

Found 698 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Four-Repeat Tauopathy Neuroimaging Initiative
99 years or below
All genders
New treatments that target the protein tau are beginning to enter human clinical trials. While tau-related therapies hold great promise for AD, clinical trials focusing on pure tauopathies are appealing because these diseases do not exhibit concurrent amyloid pathology. Pure 4 microtubule binding repeat (4R) tauopathies (4RT) include corticobasal degeneration …
 Autism Spectrum Program of Excellence
3 years - 99 years
All genders
The goal of the ASPE study is to investigate the genetic basis of Autism spectrum disorder (ASD) and autism-related traits.Individuals 3 years old or older with a diagnosis (or suspected diagnosis) of autism spectrum disorder without intellectual disability may be eligible to participate. We are also recruiting individuals with a deletion or …
18 years - 90 years
All genders
Phase 2
The purpose of this study is to see whether a drug called naltrexone improves health-related quality of life in patients with vasculitis. Naltrexone is a prescription drug approved for a different reason at a higher dose than the dose used in this study. However, “low dose naltrexone” is widely used, …
 A Phase I/II trial of olaparib  palbociclib and fulvestrant in patients with BRCA mutation-associated  hormone receptor-positive  human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer
18 years - 99 years
All genders
Phase 1
The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+) breast cancer and BRCA1 or BRCA2 mutations.
18 years - 40 years
Female
OCPs increase the risk of MetS specifically by producing an atherogenic lipoprotein phenotype, increasing blood pressure and/ or body weight while metformin modestly decreases MetS risk by decreasing body weight and improving lipid phenotype. The combination of OCP and metformin (OCP, through lowering androgens, and metformin, through improvement in insulin …
 Multicenter open-label study to evaluate efficacy of gadobutrolenhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or suspected CAD by a blinded image analysis
1 years - 99 years
All genders
Phase 3
The primary efficacy objectives of this study are to demonstrate that sensitivity and specificity of gadobutrol-enhanced CMRI exceed prespecified minimum performance thresholds (MPT) of 60% and 55%, respectively and to show superior sensitivity over unenhanced wall motion CMRI at vasodilator rest/stress for the detection of significant coronary artery disease (CAD) …
 Cardiovascular Inflammation Reduction Trial (CIRT):  A randomized  double-blind  placebo controlled  event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with type 2 diabetes or metabolic syndrome
1 years - 99 years
All genders
Phase 4
This is an event-driven, multi-center, randomized, double-blind, placebo-controlled trial to determine whether methotrexate reduces heart attacks, strokes, or death in people who have already had at least one heart attack and have type 2 diabetes or metabolic syndrome. Metabolic syndrome is defined as a combination of problems including a large …
 A Phase 2  Multi-center  Randomized  Double-Blind  Placebo-Controlled  Dose Range Finding Study to Evaluate the Safety  Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects who have Diabetic Foot Ulcer with Peripheral Arterial Disease
1 years - 99 years
All genders
Phase 2
This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have DFU with PAD. The study will enroll approximately 24 subjects. Two dose levels of PDA-002 (3 x 106 and 30 x 106 cells) versus placebo will be evaluated in 1:1:1 randomization approach. Subjects will …
18 years - 35 years
All genders
The purpose of this study is 1) to examine the acute effects of nicotine free e-cigarette aerosol on vascular function in healthy, non-smokers and 2) to examine and compare vascular function in healthy smokers chronically exposed, at baseline and after 12 months, to nicotinized e-cigarette aerosol versus conventional cigarettes as …
661 - 670 of 698